Trimel Pharmaceuticals (TSE:TRL) shares were on the rise Wednesday after reporting positive results from a phase II clinical trial of Tefina, a testtosterone nasal gel designed to treat female orgasmic disorder.
The disorder, also known as anorgasmia, is characterized by a delay, absence or reduced intensity of orgasm, often causing significant distress.
19:31 The difference between talking about Donald Trump’s accusers and being ‘fascinated by sex’10
17:10 Gene study clears 'Patient Zero' as cause of U.S. HIV epidemic14
16:28 North Carolina woman wins $1M after buying Lottery scratch-off to teach husband about ‘wasteful spending’10
00:42 Yet Another Woman Accuses Trump of Inappropriate Sexual Conduct2